Takeda’s Post

Engaging with patient associations is crucial for pharma companies since it offers a unique opportunity to understand patient needs to better improve treatments, ultimately leading to a healthier future for everyone.   For Mark Bell, General Manager UK & Ireland, and his team, dedication to supporting patient groups has been a cornerstone of their efforts. By actively engaging with these groups, they have gained important insights from patients living with rare diseases and their everyday life with the disease. This interaction has been instrumental in shaping Immedica’s approach towards patient-centric solutions.   Read more about Immedica and what we do for those living with rare diseases. www.immedica.com   #immedica #immedicapharma #rarediseases #patientadvocacy

Register now to join patients, rare disease advocates, physicians, researchers, allied health professionals and industry professionals in an externally-led patient focused drug development (EL-PFDD) meeting with the FDA this June 7, 2024. Learn more about how patients live with dermatomyositis while waiting for better targeted therapies to be developed, to help them continue to contribute to society despite having to adapt their lifestyles. Register now for the opportunity to join this meeting! #dermatomyositis #ELPFDD

The #AtlasofMS shows that in 70% of low-income countries there are no licensed MS Disease Modifying Therapies (DMTs) available for use. ‘Off-label’ treatments are those that have been approved for other conditions, but not specifically MS. The evidence-base for off-label treatments is different to treatments which have regulatory approval, but they may be the only option in low-resource settings. The World Health Organization recently included three MS medicines on their Essential Medicines List, including the off-label DMT, rituximab. Hear from Dr Shanthi Viswanathan, on why this decision is a major step forward for improving #AccessToMedicines for MS, especially in low-resource settings. Find out more about MSIF’s work on off-label treatments for MS here: https://lnkd.in/eY-qPzp9 #GlobalHealth #MSTreatmentsForAll

Addressing pain is a significant component of healthcare, ranging from short-term to long-term relief. Pharmacies and patent medicine stores play a role in this field, offering guidance on pain relief medications and collaborating with larger institutions for emergency care, disease management, and support for those with chronic pain. In the video provided, we highlight essential elements of pain management to help pharmacies and patent medicine stores enhance patient care. . #RemedialHealth #Pharmacy #PainManagement #Healthcare

"Patient registries have been recognised as important sources of data on healthcare practices, drug utilisation and clinical outcomes." Treatment development for rare diseases can face significant barriers when it comes to generating enough data on a given disease, especially within geographical boundaries. This article gives an overview of the increasing significance of patient registries in overcoming these barriers. Read more: https://zurl.co/t0RQ #patientregistries #realworldevidence #rarediseases

Have you seen this? The MPN Hub hosted an expert discussion on: How to treat cytopenic patients with MPN? KEY DISCUSSION POINTS Challenges/unmet needs Key considerations in managing cytopenic patients Different therapeutic options Led by #MPNHub steering committee member, Haifa Kathrin Al-Ali. Watch here 👉 https://loom.ly/_6tdXKU #mpnsm #cancertreatment #cancerawareness

We are delighted to inform you and your team that the Clinical management of diphtheria guideline has been published. The guideline includes 3 recommendations on : Antibiotic treatment: In patients with suspected or confirmed diphtheria, WHO recommends using macrolide antibiotics (azithromycin, erythromycin) in preference to penicillin antibiotics [Strong recommendation, low certainty evidence]. DAT sensitivity testing: In patients with suspected or confirmed diphtheria, WHO recommends not to perform routine sensitivity testing prior to administration of diphtheria antitoxin [Strong recommendation, moderate certainty evidence]. DAT dose: In patients with suspected or confirmed symptomatic diphtheria, WHO suggests administration of a single dose of diphtheria antitoxin with choice of dose based on disease severity and time since symptom onset, in comparison with a fixed dose for all patients [Conditional recommendation, very low certainty evidence]. The guideline is available on the following links: IRIS: Clinical management of diphtheria: guideline, 2 February 2024 (who.int) MAGICapp: Clinical management of diphtheria: guideline (magicapp.org) WHO website: Clinical management of diphtheria (who.int) Many thanks for your great support and continued collaboration with all our great experts ! #safescalableclincalcare #clinicaloperations #diphtheria #WHE #gdg Steve McGloughlin Jamie Rylance Julie Viry Gordon Guyatt Srinivas Murthy

Innovating to meet patient needs. As we mark #RareDiseaseDay, we are reminded of the extraordinary strength, resilience, and courage of those living with rare diseases. The paths taken by patients with rare diseases are as varied and intricate as the diseases they face. While innovations remain challenging, a clear vision, steadfast dedication, and a focus on patients are guiding us toward reshaping the treatment of rare diseases. I am both thrilled and humbled to play a role in this transformative journey. Our experiences in supporting patients with the rare kidney disease IgAN show the value novel treatment options can bring to thousands of patients’ lives. And we are not done yet – we continue to seek out more opportunities to add value and make a difference, including by working closely with trusted partners. Our Specialty Pharma segment delivers medicines to improve the lives and clinical outcomes of patients worldwide with chronic, complex or rare conditions. These medicines are integral to our purpose of Caring for People’s Health as they can address unmet medical needs and relieve financial pressures across healthcare systems. Often working through a partnership and licensing model, we are committed to becoming a partner of choice for physicians and patients by ensuring people living with chronic conditions have access to life-altering, high-quality treatments. #CaringForPeoplesHealth 

Learn more about our therapeutic focus in chronic #cough and the current unmet need in #IPF and #RCC, please visit https://ow.ly/M2AM50RuMgX. We are committed to advancing our research for patients in need. Follow our page to see our progress. #clinicaltrials #research #idiopathicpulmonaryfibrosis #RCC

Test Your Competency in Optimizing Mild-to-Moderate COVID-19 Treatment in Patients With Impaired Renal Function: A COVID-19 Clinical Case Challenge | | 0.25-hour CME/CE | Case Challenge #4 of 5 in the COVID-19 challenge series #PRIME #MedEd #cme #covid https://bit.ly/3LDJ28x